Lin C, Hsu J, Hsu Y, Fan K, Wu S, Lin M
J Enzyme Inhib Med Chem. 2025; 40(1):2468355.
PMID: 40013582
PMC: 11869342.
DOI: 10.1080/14756366.2025.2468355.
Carelock M, Master R, Kim M, Jin Z, Wang L, Maharjan C
Life Med. 2025; 2(3):lnad019.
PMID: 39872303
PMC: 11749652.
DOI: 10.1093/lifemedi/lnad019.
Feller F, Honin I, Miranda M, Weber H, Henze S, Hanl M
J Med Chem. 2025; 68(2):1824-1843.
PMID: 39804678
PMC: 11780399.
DOI: 10.1021/acs.jmedchem.4c02569.
Wang Y, Kong R, Xie K, Wang X, Wu H, Zhang Y
Genes (Basel). 2025; 15(12.
PMID: 39766786
PMC: 11675110.
DOI: 10.3390/genes15121518.
Spallotta F, Illi B
Biomedicines. 2024; 12(11).
PMID: 39595195
PMC: 11591585.
DOI: 10.3390/biomedicines12112631.
Characteristic roadmap of linker governs the rational design of PROTACs.
Dong Y, Ma T, Xu T, Feng Z, Li Y, Song L
Acta Pharm Sin B. 2024; 14(10):4266-4295.
PMID: 39525578
PMC: 11544172.
DOI: 10.1016/j.apsb.2024.04.007.
Targeted protein degradation: advances in drug discovery and clinical practice.
Zhong G, Chang X, Xie W, Zhou X
Signal Transduct Target Ther. 2024; 9(1):308.
PMID: 39500878
PMC: 11539257.
DOI: 10.1038/s41392-024-02004-x.
PROTACs Targeting Epigenetic Proteins.
Zhang C, He Y, Sun X, Wei W, Liu Y, Rao Y
Acta Mater Med. 2024; 2(4):409-429.
PMID: 39221114
PMC: 11364368.
DOI: 10.15212/amm-2023-0039.
Degraders in epigenetic therapy: PROTACs and beyond.
Dai X, Ji S, Fu M, Liu G, Liu H, Wang S
Theranostics. 2024; 14(4):1464-1499.
PMID: 38389844
PMC: 10879860.
DOI: 10.7150/thno.92526.
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
Peng X, Hu Z, Zeng L, Zhang M, Xu C, Lu B
Acta Pharm Sin B. 2024; 14(2):533-578.
PMID: 38322348
PMC: 10840439.
DOI: 10.1016/j.apsb.2023.09.003.
Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer.
Vuletic A, Mirjacic Martinovic K, Spasic J
Pharmaceutics. 2024; 16(1).
PMID: 38258065
PMC: 10818982.
DOI: 10.3390/pharmaceutics16010054.
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues.
Pichlak M, Sobierajski T, Blazewska K, Gendaszewska-Darmach E
J Enzyme Inhib Med Chem. 2023; 38(1):2254012.
PMID: 37667522
PMC: 10481767.
DOI: 10.1080/14756366.2023.2254012.
PROTAC chemical probes for histone deacetylase enzymes.
Patel U, Smalley J, Hodgkinson J
RSC Chem Biol. 2023; 4(9):623-634.
PMID: 37654508
PMC: 10467623.
DOI: 10.1039/d3cb00105a.
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation.
Xiao Y, Hale S, Awasthee N, Meng C, Zhang X, Liu Y
Cell Chem Biol. 2023; 30(11):1421-1435.e12.
PMID: 37572669
PMC: 10802846.
DOI: 10.1016/j.chembiol.2023.07.010.
Targeting histone deacetylases for cancer therapy: Trends and challenges.
Liang T, Wang F, Elhassan R, Cheng Y, Tang X, Chen W
Acta Pharm Sin B. 2023; 13(6):2425-2463.
PMID: 37425042
PMC: 10326266.
DOI: 10.1016/j.apsb.2023.02.007.
PROTACs: A novel strategy for cancer drug discovery and development.
Han X, Sun Y
MedComm (2020). 2023; 4(3):e290.
PMID: 37261210
PMC: 10227178.
DOI: 10.1002/mco2.290.
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, Niu T
Signal Transduct Target Ther. 2023; 8(1):71.
PMID: 36797244
PMC: 9935927.
DOI: 10.1038/s41392-023-01342-6.
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Liu X, Wang A, Shi Y, Dai M, Liu M, Cai H
Molecules. 2023; 28(3).
PMID: 36770884
PMC: 9919707.
DOI: 10.3390/molecules28031217.
PROTAC: targeted drug strategy. Principles and limitations.
Koroleva O, Dutikova Y, Trubnikov A, Zenov F, Manasova E, Shtil A
Russ Chem Bull. 2022; 71(11):2310-2334.
PMID: 36569659
PMC: 9762658.
DOI: 10.1007/s11172-022-3659-z.
Recent Advances of Degradation Technologies Based on PROTAC Mechanism.
Xiao M, Zhao J, Wang Q, Liu J, Ma L
Biomolecules. 2022; 12(9).
PMID: 36139095
PMC: 9496103.
DOI: 10.3390/biom12091257.
